PWUP

NASDAQ

PowerUp Acquisition Corp.

SectorFinanceIndustryBlank ChecksIPO2022

$11.92+0.43 (+3.74%)

News25/Ratings0

PowerUp Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business within the interactive media, digital media, sports, entertainment, and/or leisure areas. The company was incorporated in 2021 and is based in New York, New York.

Latest news

25 items

423dSEC
SEC Form SCHEDULE 13G filed by PowerUp Acquisition Corp.
SCHEDULE 13G - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)
428dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell C
8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
429dNEWS
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (NASDAQ:ASBP)(NASDAQ:ASBPW), today announced that it entered into a definitive Securities Purchase Agreement (the "Agreement") on February 19, 2025, pursuant to which the Company issued to the Buyers a senior secured convertible debenture (the "Debenture"). The Debenture is only convertible in the event of a default or at the Company's discretion. The closing of the transaction is expected to occur on February 20, 2025 (the "Closing Date"). The transaction will result in gross proceeds to th
429dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
430dSEC
SEC Form 25-NSE filed by PowerUp Acquisition Corp.
25-NSE - PowerUp Acquisition Corp. (0001847345) (Subject)
431dNEWS
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (NASDAQ:PWUP), a Nasdaq Global Market® listed special purpose acquisition company, ("PowerUp"), today announced the completion of their previously announced business combination (the "Business Combination"). The Business Combination was approved by PowerUp Acquisition Corp. stockholders on January 31, 2025, and it closed on February 17, 2025. Beginning on February 20, 2025, Aspire Biopharma shares of common stock and warrants will begin to trade on the Nasdaq G
439dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
485dSEC
SEC Form 425 filed by PowerUp Acquisition Corp.
425 - PowerUp Acquisition Corp. (0001847345) (Subject)
485dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
527dSEC
SEC Form 10-Q filed by PowerUp Acquisition Corp.
10-Q - PowerUp Acquisition Corp. (0001847345) (Filer)
548dSEC
Amendment: SEC Form 10-Q/A filed by PowerUp Acquisition Corp.
10-Q/A - PowerUp Acquisition Corp. (0001847345) (Filer)
548dSEC
Amendment: SEC Form 10-Q/A filed by PowerUp Acquisition Corp.
10-Q/A - PowerUp Acquisition Corp. (0001847345) (Filer)
562dSEC
SEC Form 425 filed by PowerUp Acquisition Corp.
425 - PowerUp Acquisition Corp. (0001847345) (Subject)
562dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
568dSEC
SEC Form 425 filed by PowerUp Acquisition Corp.
425 - PowerUp Acquisition Corp. (0001847345) (Subject)
568dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
596dSEC
SEC Form 425 filed by PowerUp Acquisition Corp.
425 - PowerUp Acquisition Corp. (0001847345) (Subject)
596dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
600dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
600dPR
Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements
Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel delivery mechanisms to enhance the efficacy of "do no harm" FDA approved drugs, nutraceuticals and supplements.Innovative Drug Delivery Technology: Aspire's patented and patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs directly into the blood stream, thus on first pass, avoiding the gastrointestinal tract and liver, mitigating unwanted toxicity of this critical organ.Growth and
603dSEC
SEC Form 425 filed by PowerUp Acquisition Corp.
425 - PowerUp Acquisition Corp. (0001847345) (Subject)
603dSEC
PowerUp Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
617dSEC
SEC Form 10-Q filed by PowerUp Acquisition Corp.
10-Q - PowerUp Acquisition Corp. (0001847345) (Filer)
619dSEC
SEC Form NT 10-Q filed by PowerUp Acquisition Corp.
NT 10-Q - PowerUp Acquisition Corp. (0001847345) (Filer)
631dSEC
SEC Form RW filed by PowerUp Acquisition Corp.
RW - PowerUp Acquisition Corp. (0001847345) (Filer)